GLP-1 Combination Reduced Endometrial Cancer Risk by 66%, Study Finds Pharmacy Times
Endometriosis is a complex, estrogen-dependent disease with limited effective treatments that often focus on symptom management rather than addressing the underlying pathology. Current therapies, such as progestins and GnRH agonists, …
Elagolix sodium (ELS), a non-peptide oral gonadotropin-releasing hormone receptor (GnRH) antagonist approved for the treatment of endometriosis-associated pain, displays atypical gelation in aqueous environments along with challenging physical properties such …
Endometriosis affects 10% of women of childbearing age and 25-50% of infertile women worldwide. Although most patients with endometriosis are completely asymptomatic, there is still a significant proportion of patients, …
This report describes two women aged 45 and older who achieved live births following intraovarian administration of a novel combination of mechanically processed adipose nanofat rich in adipose-derived stem cells …
New Combination Therapy Shows Promise for pMMR Advanced Endometrial Cancer in Phase Ib/II Trial geneonline.com
Background/Objectives: The assessment of endometriosis (EMS)-associated pain is important, but only very few studies address the potential use of questionnaires for non-invasive prediction of the disease. Methods: In a prospective …
Phase 3 RUBY Trial: Dostarlimab Combination Prolongs Time to Next Treatment for Endometrial Cancer Cancer Nursing Today
Phase 3 RUBY Trial: Dostarlimab Combination Prolongs Time to Next Therapy for Advanced Endometrial Cancer Cancer Nursing Today
To study the impact of estetrol (E4), a novel native estrogen with selective tissue activity, on endometriosis-associated pelvic pain (EAPP) and global impressions of endometriosis pain.